
Adapted from BMJ 14 June 2025
Observational studies have shown that colon cancer patients who increase their physical activity after treatment have a lower risk of recurrence and death compared to those who don’t. Now, a randomised controlled trial, the first of its kind, has shown the same thing.
A three year programme of structured exercise reduced the relative risk of disease recurrence, new primary cancer, or death, by 28% in patients with stage III and high risk stage II colon cancer. The magnitude of the benefit is on a par to many standard drug treatments.
The Challenge Study randomised 889 patients with resected colon cancer and adjuvant chemotherapy to either the structured exercise group or a health education group. The exercise group had face to face coaching sessions and behavioural support every week for the first six months and then once a month. The health education group were given information about healthy eating and exercise but not the personal coaching.
The exercise group managed to get people to do the equivalent of 40-60 minutes brisk walking or 25-30 minutes of jogging, three or four times a week.
After 8 years follow up, disease recurrence, new primary cancer, or death had occurred in 93 of the 445 people in the exercise group, compared with 131 of 444 people in the education group. 90% of the exercise group were still alive, compared to 83% in the education group.
Vicky Coyle, consultant medical oncologist at Queen’s University Belfast, who led the research, hopes that exercise will be embedded in future treatment plans for patients.
It is thought that exercise works by regulating hormone levels, reducing inflammation and strengthening the immune system.
One of the commonest questions patients ask their doctors is what they can do to reduce their risk of a cancer recurrence. A vigorous, structured exercise programme fits the bill.








